Database for Interstitial Lung Disease

Lung Diseases, Interstitial Clinical Trial

Official title:

Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04707781
• Other study ID #: 33-023 ex 20/21
• Status: Recruiting
• Start date: May 1, 2021
• Est. completion date: January 31, 2026

Study information

• Verified date: May 2023
• Source: Medical University of Graz
• Contact: Gabor Kovacs, MD
• Phone: +43-316-385
• Email: gabor.kovacs[@]klinikum-graz.at
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 412
• Est. completion date: January 31, 2026
• Est. primary completion date: January 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age: = 18 years
• patients with a known systemic disease bearing a risk for ILD
• signed informed consent (for prospective part)

Exclusion Criteria:

• Age < 18 years
• comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)

Related Conditions & MeSH terms

• Lung Diseases
• Lung Diseases, Interstitial

Intervention

Diagnostic Test:
• chest CT
assessment of interstitial lung disease using chest CT

Locations

Country	Name	City	State
Austria	Medical University of Graz, Department of Internal Medicine, Division of Pulmonology	Graz

Sponsors (2)

Lead Sponsor	Collaborator
Medical University of Graz	Boehringer Ingelheim

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DLCO%pred (carbon monoxide diffusing capacity) at time of ILD diagnosis	The investigators aim to assess DLCO% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the DLCO%pred at time of ILD diagnosis	5 years
Secondary	FVC%pred (Forced vital capacity) at time of ILD diagnosis	The investigators aim to assess FVC% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the FVC%pred at time of ILD diagnosis	5 years